Gilead blocks HIV drug generics for more than 10 years

The pharma giant extends market exclusivity for a top-selling drug accounting for nearly half of its multi-billion-dollar sales.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Gilead deal staves off generic HIV drugs for another six years

20 February 2025 Market leader settles patent disputes with generic drug makers, blocking the release of versions of two key products | More than 80% of HIV patients in the US use Gilead’s treatments.

Americas

Gilead awarded $30m over counterfeit HIV drug scheme

26 November 2024 Wholesaler ‘bought nearly 17,000 bottles of fake Gilead drugs’ | US government says defendant sentenced in September should pay company for lost profits.

Americas

LSPN Fall: Gilead GC shares top drafting tips

17 October 2024 At LSPN Fall North America, in-house counsel offered guidance on how to nail the perfect patent application. Marisa Woutersen reports.

More features

Novo Nordisk counters rival with $9bn bid for obesity drug developer

‘We're being attacked from all sides’: Thermo Fisher Scientific counsel

China trademarks rankings reveal new entries, hidden gems and big brands

Edwards defends key heart valve product from infringement threat

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

The hidden code in life sciences deals

Why AI is changing the patent rules faster than anyone can keep up

LSPN panel unpacks critical IP risks in deal-making

Gilead blocks HIV drug generics for more than 10 years

More on this story

Editor's picks

Editor's picks

More features